Levis, M. J., Perl, A. E., Altman, J. K., Gocke, C. D., Bahceci, E., Hill, J., . . . Miller, J. E. (2018). A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations. Blood Adv.
Stile di citazione ChicagoLevis, Mark J., et al. "A Next-generation Sequencing–based Assay for Minimal Residual Disease Assessment in AML Patients With FLT3-ITD Mutations." Blood Adv 2018.
Citazione MLALevis, Mark J., et al. "A Next-generation Sequencing–based Assay for Minimal Residual Disease Assessment in AML Patients With FLT3-ITD Mutations." Blood Adv 2018.
Attenzione: Queste citazioni potrebbero non essere precise al 100%.